Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET)

Cancer Treatment Reviews

Volumn 22, Issue 6, 1996, Pages 425-436

  Maurel, Joan ^a   Rosell, Rafael ^a   Lorenzo, Juan Carlos ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

CANCER STAGING; EWING SARCOMA; HUMAN; NEUROECTODERM TUMOR; PROGNOSIS; REVIEW;

EID: 0030426494     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90024-9     Document Type: Review

References (80)

1. Lipinski, M., Braham, K., Philip, I. et al. (1987) Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res. 47: 183-187.
2. Ushigome, S., Shimoda, T., Takaki, K. et al. (1989) Inmunocytochemical and ultrastructural studies of the histogenesis of Ewing's sarcoma and putatively related tumours. Cancer 64: 52-62.
3. Schmidt, D., Herrmann, C., Jürgens, H. & Harms, D. (1991) Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. Cancer 68: 2251-2259.
4. Jürgens, H., Paulussen, M., Roessner, A. et al. (1993) Neural differentiation in small round cell sarcomas of bone in children and adolescents: Implications for treatment? Proc. Am. Soc. Clin. Oncol. 12: 1415.
5. Delattre, O., Zucman, J., Plougastel, B. et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
6. Pellin, A., Boix, J., Blesa, J. R., Noguera, R., Carda, C. & Llombart-Bosch, A. (1993) EWS/FLI1 rearrangement in small round cell sarcomas of bone and soft tissue detected by reverse transcriptase polymerase chain reaction amplification. Eur. J. Cancer 30: 827-831.
7. Delattre, O., Zucman, J., Melot, T. et al. (1994) The Ewing family of tumors. A subgroup of small-round-cell tumors defined by specific chimeric transcripts. New Engl. J. Med. 331: 294-299.
8. Jeon, I. S., Davis, J. N., Braun, B. S. et al. (1995) A variant Ewing's sarcoma translocation (7; 22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10: 1229-1234.
9. Fellinger, E. J., Garin-Chesa, P., Su, S. L. etal. (1991) Biochemical and genetic characterization of the HBA71 Ewing's sarcoma cell surface antigen. Cancer Res. 51: 336-340.
10. Garin-Chesa, P., Swanson, P. I., Rettig, W. J. & Huvos, A. G. (1993) Inmunohistochemical analysis of small round cell tumours for expression of the MIC2 gene product (HBA71 antigen). Mod. Pathol. 6: 6A
11. Weidner, N. & Tjoe, T. (1994) Inmunohistochemical profile of monoclonal antibody O13: Antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am. J. Surg. Pathol. 18: 486-494.
12. Komuro, H., Hayashi, Y, Kawamura, M. et. al. (1993) Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 53: 5284-5288.
13. Hamelin, R., Zucman, J., Melot, T. et al. (1994) P53 mutations in human tumours with chimeric EWS/FLI-1 genes. Int. J. Cancer 57: 336-340.
14. Kovar, H., Auinger, A., Jug, G. et al. (1993) Narrow spectrum of infrequent p53 mutations and absence of mdm2 amplification in Ewing tumours. Oncogene 8: 2683-2690.
15. Ladanyi, M., Lewis, R., Jhawar, S. C. et al. (1995) Mdm2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathol. 175: 211-217.
16. Hijazi, Y. M., Axiotis, C. A., Navarro, S. et al. (1994) Immunohistochemical detection of p-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Anat. Pathol. 102: 61-67.
17. Roessner, A., Ueda, Y., Bockhorn-Dworniczak, B. et al. (1993) Prognostic implication of inmunodetection of P-glycoprotein in Ewing's sarcoma. J. Cancer Res. Clin. Oncol. 119: 185-189.
18. Chan, H. S., Haddad, G., Thorner, P. S., DeBoer, G. & Ling, V. (1993) P-glycoprotein expression as a predictor of the outcome of therapy for Ewing's sarcoma. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34: 000.
19. Jun, L., Johnston, O., Laskin, W. et al. (1996) P53 and thymidilate synthase (TS) expression by desmoplastic small round cell tumours (DSRCT). Proc. Am. Soc. Clin. Oncol. 15: 466.
20. Jürgens, H., Exner, U., Gadner, H. et al. (1987) Multidisciplinary treatment of primary Ewing's sarcoma of bone-A 6 years experience of a European Cooperative Trial. Cancer 61: 23-32.
21. Cangir, A., Vietti, T. J., Gehan, E. A. et al. (1990) Ewing's sarcoma metastatic at diagnosis: results and comparisons of two intergroup Ewing's Sarcoma Studies. Cancer 66: 887-893.
22. Nesbit, M. E., Gehan, E. A., Burgert, E. O. et al. (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long term follow-up of the First Intergroup Study. J. Clin. Oncol. 10: 1664-1674.
23. Burgert, E. O., Nesbit, M. E., Garnsey, L. A. et al. (1990) Multimodal therapy for the management of non-pelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J. Clin. Oncol. 10: 1514-1524.
24. Picci, P., Sangiorgi, L., Bahamonde, L. et al. (1994) Outcome of patients with non-metastatic Ewing's sarcoma of the pelvis: results in 65 patients. Proc. Am. Soc. Clin. Oncol. 13: 475.
25. Miser, J. S., Krailo, M., Meyers, P. et al. (1996) Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: failure of new regimens to improve outcome. Proc. Am. Soc. Clin. Oncol. 15: 467.
26. Picci, P., Rougraff, B. T., Bacci, G. et al. (1993) Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J. Clin. Oncol. 11: 1763-1769.
27. Meyers, P. A., Wunder, J., Healey, J., Paulian, G. & Huvos, A. (1995) Ewing's sarcoma (ES)/ peripheral primitive neuroectodermal tumors (PNET): Histological response (HR) to preoperative chemotherapy (CT) predicts event free survival (EFS). Proc. Am. Soc. Clin. Oncol. 15: 441.
28. Oberlin, O., Habrand, J. L., Zucker, J. M. et al. (1992) No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of pediatric oncology. J. Clin. Oncol. 10: 1407-1412.
29. Chen, G., Jaffrézou, J. P., Fleming, W. et al. (1994) Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 54: 4980-4987.
30. Scotlandi, K., Serra, M., Nicoletti, G. et al. (1996) Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 56: 2434-2439.
31. Chan, H. S. L., Thorner, P. S., Haddad, G. & Ling, V. (1990) Inmunohistochemical detection of p-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8: 689-704.
32. Kuttesch, J., Parham, D., Luo, X. et al. (1996) P-glycoprotein (PGP) expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J. Clin. Oncol. 14: 886-900.
33. Baldini, N., Scotlandi, K., Barbanti-Brodano, G. et al. (1995) P-glycoprotein expression and outcome in high-grade osteosarcoma. N. Engl. J. Med. 333: 1380-1385.
34. Lowe, S. W., Bodis, S., McClatchey, A. et al. (1994) P53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
35. Chresta, C. M., Masters, J. R. & Hickman, J. A. (1995) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax.Bcl2 ratio. Cancer Res. 56: 1834-1841.
36. Perego, P., Giarola, M., Righetti, S. C. et al. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56: 556-562.
37. Righetti, S. C., Della Torre, G., Pilotti, S. et al. (1996) A comparative study of p53 gene mutations, protein acumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56: 689-693.
38. Wahl, A. F., Donaldson, K. L., Fairchild, C. et al. (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med. 2: 72-79.
39. Kat, A., Thilly, W. G., Fang, W.-H., Longley, M. J., Li, G.-M. & Modrich, P. (1993) An alkylationtolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. 90: 6424-6428.
40. Branch, P., Aquilina, G., Bignami, M. & Karran, P. (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654.
41. Anthoney, D. A., Mcllwrath, A. J., Gallagher, W. M., Edlin, A. R. M. & Brown, R. (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res. 56: 1374-1381.
42. Rosen, G., Capparos, B., Nirenberg, A. et al. (1981) Ten years experience with adjuvant chemotherapy. Cancer 47: 2204-2213.
43. Bacci, G., Picci, P., Gitelis, S. et al. (1982) The treatment of localized Ewing's sarcoma: the experience at the instituto Ortopedico Rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer 49: 1561-1570.
44. Dunst, J., Burgers, J. M. V., Hawliczek, R. et al. (1991) Radiation therapy as local treatment in Ewing's sarcoma. Cancer 67: 2818-2825.
45. Evans, R. G., Nesbit, M. E., Gehan, E. A. et al. (1991) Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: A report from the Second Intergroup Study. J. Clin. Oncol. 9: 1173-1180.
46. Scully, S. P., Temple, H. T., O'Keefe, R. J., Scarborough, M. T., Mankin, H. J. & Gebhardt, M. C. (1995) Role of surgical resection in pelvic Ewing's sarcoma. J. Clin. Oncol. 13: 2336-2341.
47. Jaffe, N., Paed, D., Traggis, D. et al. (1976) Improved outlook for Ewing sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38: 1925-1930.
48. Rosen, G., Wollner, N., Tan, C. et al. (1974) Disease free survival in children with Ewing's sarcoma treated with sequential chemotherapy. Cancer 33: 384-393.
49. Oberlin, O., Patte, C., Demeocq, F. et al. (1985) The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur. J. Cancer 21: 463-467.
50. Oberlin, O., Bui, N. B., Brunat-Mentigny, M. et al. (1996) Young adults with localised Ewing's sarcoma: the experience of the French Society of Pediatric Oncology. Proc. Am. Soc. Clin. Oncol. 15: 523.
51. Wilkins, R. M., Pritchard, D. J., Burgert, E. O. & Unni, K. K. (1986) Ewing's sarcoma of bone-experience with 140 patients. Cancer 58: 2551-2555.
52. Hayes, F. A., Thompson, E. I., Meyer, W. H. et al. (1989) Therapy for localized Ewing's sarcoma of bone. J. Clin, Oncol. 7: 208-213.
53. Kinsella, T. J., Miser, J. S., Waller, B. et al. (1991) Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 20: 389-395.
54. Aparicio, J., Munérriz, B., Pastor, M. et al. (1996) Multivariate analysis of prognostic factors (PFs) in 96 patients with localized Ewing's sarcoma (ES) of bone and soft tissues. Proc. Ann. Oncol. 7: (Suppl. 5) 121.
55. Meyer, W. H., Kun, L., Marina, N. et al. (1992) Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J. Clin. Oncol. 11: 1737-1742.
56. Grier, H., Krailo, M., Link, M. et al. (1994) Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adriamycin (Ad), cyclophosphamide (C) and actinomycin (A). A children's cancer group (CCG) and pediatric oncology group (POG) report. Proc. Am. Soc. Clin. Oncol. 14: 451.
57. Kinsella, T. J., Glaubiger, D., Diesseroth, A. et al. (1983) Intensive combined modality therapy including low-dose TBI in high risk Ewing's sarcoma patients. Int. J. Radiat. Oncol. Biol. Phys. 9: 1955-1960.
58. Marcus, R. B., Graham-Pole, J. R., Springfield, D. S. et al. (1988) High-risk Ewing's sarcoma: End-intensification using autologous bone marrow transplantation. Int. J. Radiat. Oncol. Biol. Phys. 15: 53-59.
59. Miser, J. S., Kinsella, T. J., Triche, T. J. et al. (1988) Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J. Clin. Oncol. 6: 484-490.
60. Horowith, M. E., Kinsella, T. J., Wexler, L. H. et al. (1993) Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J. Clin. Oncol. 11: 1911-1918.
61. Meyers, P. A., Gardner, S., Lindsley, K. et al. (1995) High-risk Ewing's sarcoma (EWS)/primitive neuroectodermal tumor (PNET) of bone: consolidation with total body irradiation (TBI), melphalan and autologous stem cell reconstitution. Proc. Am. Soc. Clin. Oncol. 14: 451.
62. Rosito, P., Tienghi, A., Pession, A. et al. (1996) Peripheral blood stem cell transplantation (PBSCT) in high risk Ewing sarcoma (HR-EwS). Proc. Am. Soc. Clin. Oncol. 15: 337.
63. Evans, R. G., Burgert, O., Gilchrist, G. S. et al. (1984) Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma - A pilot study. Int. J. Radiat. Oncol. Biol. Phys. 10: 2363-2368.
64. Cornbleet, M. A., Corringham, R. E. T., Prentice, G. H. et al. (1981) Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat. Rep. 65: 241.
65. Ladenstein, R., Lasset, C., Pinkerton, R. et al. (1995) Impact of megatherapy in children with high-risk Ewing's tumours in complete remission. A report from the EBMT solid tumour registry. Bone Marrow Transp. 15: 697-705.
66. Michon, J., Hartmann, O., Demeocq, F. et al. (1994) Consolidation with busulfan and melphalan followed by blood progenitor cell (BPC) graft in children and young adults with high-risk Ewing sarcoma: A report of the French Society of Pediatric Oncology (SFOP). Proc. Am. Soc. Clin. Oncol. 13: 414.
67. Stewart, D. A., Russell, J. A., Temple, W., Schachar, N. S. & Paterson, A. H. G. (1995) High dose melphalan (HDM) +/- total body irrradiation (TBI) followed by autologous hematopoietic stem cell transplantation (ASCT) for adult patients with Ewing's sarcoma (EWS) or peripheral neuroectodermal tumors (PNET). Proc. Am. Soc. Clin. Oncol. 14: 517.
68. Burdach, S., Jürgens, H., Peters, C. et al. (1993) Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J. Clin. Oncol. 11: 1482-1488.
69. Frei, E. III, Teicher, B. A., Holden, S. A. et al. (1988) Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 46: 6417-6423.
70. Smith, M. A., Ungerleider, R. S., Horowith, M. E. & Simon, R. (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl. Cancer Inst. 20: 1460-1470.
71. Kushner, B. H., Meyers, P. A., Gerald, W. L. et al. (1995) Very-high-dose short-term chemotherapy for peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J. Clin. Oncol. 13: 2796-2804.
72. Womer, R. (1993) Personal communication.
73. Miser, J. S., Kinsella, T. J., Triche, T. J. et al. (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. 5: 1191-1198.
74. Kung, F. H., Pratt, C. B., Vega, R. A. et al. (1992) Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. Cancer 71: 1898-1903.
75. Lewis, I. J., Stevens, M. C. G., Pearson, A., Pinkerton, C. R. & Stevens, R. (1993) Phase II study of carboplatin in children's tumours. Proc. Am. Soc. Clin. Oncol. 12: 412.
76. Cairo, M. S., Krailo, M., Miser, J. et al. (1996) Excellent results of the use of ifosfamide, carboplatin, etoposide (ICE) in children with recurrent or refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 15: 468.
77. Legha, S. S., Benjamin, R. S., Mackay, B. et al. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 96: 133-139.
78. Novakovic, B., Fears, T. R., Horowith, M. E., Tucker, M. A. & Wexler, L. H. (1996) Health status, functional status and health insurance in survivors of Ewing's sarcoma family (ESFT) tumors. Proc. Am. Soc. Clin. Oncol. 14: 457.
79. Kuttesch, J., Wexler, L., Marcus, R. et al. (1993) Second malignant neoplasm (SMN) after Ewing's sarcoma (ES). Proc. Am. Soc. Clin. Oncol. 12: 419.
80. Green, D., Zevon, M. & Lowrie, G. (1995) Doxorubicin is a significant risk factor for second malignant tumors (SMTs) after treatment for childhood cancer. Proc. Am. Soc. Clin. Oncol. 14: 438.